The efficacy of clarithromycin-containing triple therapy (TT) against Helicobacter pylori has declined in Korea, with recent first-line eradication rates falling below 70%. Clarithromycin resistance exceeded 30%, undermining the standard regimen for H. pylori. These trends necessitate a change in the treatment strategy. This review analyzed the shift proposed in the draft of the 2025 Korean H. pylori guidelines. We examined the rationale for abandoning TT as a first-line empirical therapy and the establishment of a new dual-pillar strategy: 1) the declining role of clarithromycin-containing TT as a first-line treatment and 2) polymerase chain reaction (PCR)-based tailored therapy as the recommended precision approach. We explored the 1) emergence of new empirical regimen options, 2) application of tailored therapy, and 3) adoption of potassium-competitive acid blockers (P-CABs). Empirical regimens have shifted toward four-drug combinations to achieve higher cure rates. Concomitant therapy (proton-pump inhibitor [PPI] or P-CAB+amoxicillin+clarithromycin+metronidazole) offers high efficacy but raises concerns about antibiotic overuse. As a compromise, bismuth-augmented triple regimens (adding bismuth to TT) are now recommended; these modified quadruple therapies (e.g., PACB: PPI+amoxicillin+clarithromycin+bismuth, or PAMB: PPI+amoxicillin+metronidazole+bismuth) significantly improve eradication rates without requiring a third antibiotic class. Regarding tailored therapy, PCR-based domestic clinical research data consistently achieves ≥90% cure rates in first-line treatment—markedly higher than empirical TT in Korea. Economic analyses supported the cost-effectiveness of this approach. The guideline algorithm for salvage therapy was clarified. Bismuth quadruple therapy has been confirmed as the standard second-line treatment. For third-line therapy, we analyzed the efficacy of levofloxacin-based regimens, rifabutin-based therapy, and bismuth add-on therapy with two previously unused antibiotics. The 2025 Korean guidelines establish quadruple therapies as the new standard through a dual strategy: pragmatic empirical treatment and PCR-guided tailored therapy, with P-CABs and bismuth-based regimens as key components.

Objective: Multiple cohort studies have investigated the potential link between anesthesia and dementia. However, mixed findings necessitate closer examination. This study aimed to investigate the association between anesthesia exposure and the incidence of dementia, considering different anesthesia types and anesthetic agents. Methods: This nationwide cohort study utilized data from the South Korean Health Insurance Review and Assessment Service database, covering 62,541 participants, to investigate the correlation between anesthesia exposure and dementia incidence. Results: Results revealed an increased risk of dementia in individuals who underwent general (hazard ratio [HR], 1.318;95% confidence interval [CI], 1.061−1.637) or regional/local anesthesia (HR, 2.097; 95% CI, 1.887−2.329) compared to those who did not. However, combined general and regional/local anesthesia did not significantly increase dementia risk (HR, 1.097; 95% CI, 0.937−1.284). Notably, individual anesthetic agents exhibited varying risks; desflurane and midazolam showed increased risks, whereas propofol showed no significant difference. Conclusion This study provides unique insights into the nuanced relationship between anesthesia, individual anesthetic agents, and the incidence of dementia. While confirming a general association between anesthesia exposure and dementia risk, this study also emphasizes the importance of considering specific agents. These findings under-score the need for careful evaluation and long-term cognitive monitoring after anesthesia.

Background: To investigate the feasibility of the antegrade supraspinatus advancement (ASSA), which could be executed entirely arthroscopically without requiring a medial incision; to evaluate the impact of the ASSA on the lateral excursion of the torn end of the supraspinatus in retracted irreducible rotator cuff tears (RIRCTs); and to assess the safety and efficacy of arthroscopic rotator cuff repair with the ASSA. Methods: A total of 57 patients with RIRCTs who underwent the ASSA and were followed up for at least a year with magnetic resonance imaging (MRI) were included. The RIRCT was defined as the lateral excursion grade C (coverage less than the medial half of the greater tuberosity) or D (exposure of the glenohumeral joint). Clinical outcomes assessed nerve injury, pain, range of motion, strength, functional scores, and overall satisfaction and function. Structural outcomes evaluated the retear rate, fatty infiltration, and muscle atrophy of the rotator cuff muscles. The baseline for these structural measurements was time-zero MRIs. Results: The ASSA was feasibly performed all arthroscopically without a medial incision. There was no suprascapular nerve injury during the follow-up. The ASSA increased lateral excursion of the torn end in 86% of the patients from C or D to A or B. The ASSA significantly reduced pain and improved function of the shoulder at the final follow-up. All 11 patients who had had pseudoparalysis prior to repair regained the ability to raise their arm. The retear rate after the ASSA was 18.4%. Conclusions This study demonstrated that the ASSA can be safely and effectively performed all arthroscopically, significantly increasing the lateral excursion of the supraspinatus, thereby ensuring successful rotator cuff repair. This leads to a superior quality of repair, which consequently results in better clinical and structural outcomes, including the reversal of pseudoparalysis.

Background: and Purpose: Plasma biomarkers, including phosphorylated tau (ptau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), are promising tools for detecting Alzheimer’s disease (AD) pathology. However, cross-laboratory reproducibility remains a challenge, even when using identical analytical platforms such as single-molecule array (Simoa). This study aimed to compare plasma biomarker measurements (ptau217, GFAP, and NfL) between 2 laboratories, the University of Gothenburg (UGOT) and DNAlink, and evaluate their associations with amyloid positron emission tomography (PET) imaging. Methods: Plasma biomarkers were measured using Simoa platforms at both laboratories:the UGOT and DNAlink Incorporation. Diagnostic performance for predicting amyloid PET positivity, cross-laboratory agreement, and the impact of normalization techniques were assessed. Bland-Altman plots and correlation analyses were employed to evaluate agreement and variability. Results: Plasma ptau217 concentrations exhibited strong correlations with amyloid PET global centiloid values, with comparable diagnostic performance between laboratories (area under the curve=0.94 for UGOT and 0.95 for DNAlink). Cross-laboratory agreement for ptau217 was excellent (r=0.96), improving further after natural log transformation. GFAP and NfL also demonstrated moderate to strong correlations (r=0.86 for GFAP and r=0.99 for NfL), with normalization reducing variability. Conclusions Plasma biomarker measurements were consistent across laboratories using identical Simoa platforms, with strong diagnostic performance and improved agreement after normalization. These findings support the scalability of plasma biomarkers for multicenter studies and underscore their potential for standardized applications in AD research and clinical practice.

Objective: Multiple cohort studies have investigated the potential link between anesthesia and dementia. However, mixed findings necessitate closer examination. This study aimed to investigate the association between anesthesia exposure and the incidence of dementia, considering different anesthesia types and anesthetic agents. Methods: This nationwide cohort study utilized data from the South Korean Health Insurance Review and Assessment Service database, covering 62,541 participants, to investigate the correlation between anesthesia exposure and dementia incidence. Results: Results revealed an increased risk of dementia in individuals who underwent general (hazard ratio [HR], 1.318;95% confidence interval [CI], 1.061−1.637) or regional/local anesthesia (HR, 2.097; 95% CI, 1.887−2.329) compared to those who did not. However, combined general and regional/local anesthesia did not significantly increase dementia risk (HR, 1.097; 95% CI, 0.937−1.284). Notably, individual anesthetic agents exhibited varying risks; desflurane and midazolam showed increased risks, whereas propofol showed no significant difference. Conclusion This study provides unique insights into the nuanced relationship between anesthesia, individual anesthetic agents, and the incidence of dementia. While confirming a general association between anesthesia exposure and dementia risk, this study also emphasizes the importance of considering specific agents. These findings under-score the need for careful evaluation and long-term cognitive monitoring after anesthesia.

Background: To investigate the feasibility of the antegrade supraspinatus advancement (ASSA), which could be executed entirely arthroscopically without requiring a medial incision; to evaluate the impact of the ASSA on the lateral excursion of the torn end of the supraspinatus in retracted irreducible rotator cuff tears (RIRCTs); and to assess the safety and efficacy of arthroscopic rotator cuff repair with the ASSA. Methods: A total of 57 patients with RIRCTs who underwent the ASSA and were followed up for at least a year with magnetic resonance imaging (MRI) were included. The RIRCT was defined as the lateral excursion grade C (coverage less than the medial half of the greater tuberosity) or D (exposure of the glenohumeral joint). Clinical outcomes assessed nerve injury, pain, range of motion, strength, functional scores, and overall satisfaction and function. Structural outcomes evaluated the retear rate, fatty infiltration, and muscle atrophy of the rotator cuff muscles. The baseline for these structural measurements was time-zero MRIs. Results: The ASSA was feasibly performed all arthroscopically without a medial incision. There was no suprascapular nerve injury during the follow-up. The ASSA increased lateral excursion of the torn end in 86% of the patients from C or D to A or B. The ASSA significantly reduced pain and improved function of the shoulder at the final follow-up. All 11 patients who had had pseudoparalysis prior to repair regained the ability to raise their arm. The retear rate after the ASSA was 18.4%. Conclusions This study demonstrated that the ASSA can be safely and effectively performed all arthroscopically, significantly increasing the lateral excursion of the supraspinatus, thereby ensuring successful rotator cuff repair. This leads to a superior quality of repair, which consequently results in better clinical and structural outcomes, including the reversal of pseudoparalysis.

Background: and Purpose: Plasma biomarkers, including phosphorylated tau (ptau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), are promising tools for detecting Alzheimer’s disease (AD) pathology. However, cross-laboratory reproducibility remains a challenge, even when using identical analytical platforms such as single-molecule array (Simoa). This study aimed to compare plasma biomarker measurements (ptau217, GFAP, and NfL) between 2 laboratories, the University of Gothenburg (UGOT) and DNAlink, and evaluate their associations with amyloid positron emission tomography (PET) imaging. Methods: Plasma biomarkers were measured using Simoa platforms at both laboratories:the UGOT and DNAlink Incorporation. Diagnostic performance for predicting amyloid PET positivity, cross-laboratory agreement, and the impact of normalization techniques were assessed. Bland-Altman plots and correlation analyses were employed to evaluate agreement and variability. Results: Plasma ptau217 concentrations exhibited strong correlations with amyloid PET global centiloid values, with comparable diagnostic performance between laboratories (area under the curve=0.94 for UGOT and 0.95 for DNAlink). Cross-laboratory agreement for ptau217 was excellent (r=0.96), improving further after natural log transformation. GFAP and NfL also demonstrated moderate to strong correlations (r=0.86 for GFAP and r=0.99 for NfL), with normalization reducing variability. Conclusions Plasma biomarker measurements were consistent across laboratories using identical Simoa platforms, with strong diagnostic performance and improved agreement after normalization. These findings support the scalability of plasma biomarkers for multicenter studies and underscore their potential for standardized applications in AD research and clinical practice.

Objective: Multiple cohort studies have investigated the potential link between anesthesia and dementia. However, mixed findings necessitate closer examination. This study aimed to investigate the association between anesthesia exposure and the incidence of dementia, considering different anesthesia types and anesthetic agents. Methods: This nationwide cohort study utilized data from the South Korean Health Insurance Review and Assessment Service database, covering 62,541 participants, to investigate the correlation between anesthesia exposure and dementia incidence. Results: Results revealed an increased risk of dementia in individuals who underwent general (hazard ratio [HR], 1.318;95% confidence interval [CI], 1.061−1.637) or regional/local anesthesia (HR, 2.097; 95% CI, 1.887−2.329) compared to those who did not. However, combined general and regional/local anesthesia did not significantly increase dementia risk (HR, 1.097; 95% CI, 0.937−1.284). Notably, individual anesthetic agents exhibited varying risks; desflurane and midazolam showed increased risks, whereas propofol showed no significant difference. Conclusion This study provides unique insights into the nuanced relationship between anesthesia, individual anesthetic agents, and the incidence of dementia. While confirming a general association between anesthesia exposure and dementia risk, this study also emphasizes the importance of considering specific agents. These findings under-score the need for careful evaluation and long-term cognitive monitoring after anesthesia.

Background: To investigate the feasibility of the antegrade supraspinatus advancement (ASSA), which could be executed entirely arthroscopically without requiring a medial incision; to evaluate the impact of the ASSA on the lateral excursion of the torn end of the supraspinatus in retracted irreducible rotator cuff tears (RIRCTs); and to assess the safety and efficacy of arthroscopic rotator cuff repair with the ASSA. Methods: A total of 57 patients with RIRCTs who underwent the ASSA and were followed up for at least a year with magnetic resonance imaging (MRI) were included. The RIRCT was defined as the lateral excursion grade C (coverage less than the medial half of the greater tuberosity) or D (exposure of the glenohumeral joint). Clinical outcomes assessed nerve injury, pain, range of motion, strength, functional scores, and overall satisfaction and function. Structural outcomes evaluated the retear rate, fatty infiltration, and muscle atrophy of the rotator cuff muscles. The baseline for these structural measurements was time-zero MRIs. Results: The ASSA was feasibly performed all arthroscopically without a medial incision. There was no suprascapular nerve injury during the follow-up. The ASSA increased lateral excursion of the torn end in 86% of the patients from C or D to A or B. The ASSA significantly reduced pain and improved function of the shoulder at the final follow-up. All 11 patients who had had pseudoparalysis prior to repair regained the ability to raise their arm. The retear rate after the ASSA was 18.4%. Conclusions This study demonstrated that the ASSA can be safely and effectively performed all arthroscopically, significantly increasing the lateral excursion of the supraspinatus, thereby ensuring successful rotator cuff repair. This leads to a superior quality of repair, which consequently results in better clinical and structural outcomes, including the reversal of pseudoparalysis.

Background: and Purpose: Plasma biomarkers, including phosphorylated tau (ptau217), glial fibrillary acidic protein (GFAP), and neurofilament light chain (NfL), are promising tools for detecting Alzheimer’s disease (AD) pathology. However, cross-laboratory reproducibility remains a challenge, even when using identical analytical platforms such as single-molecule array (Simoa). This study aimed to compare plasma biomarker measurements (ptau217, GFAP, and NfL) between 2 laboratories, the University of Gothenburg (UGOT) and DNAlink, and evaluate their associations with amyloid positron emission tomography (PET) imaging. Methods: Plasma biomarkers were measured using Simoa platforms at both laboratories:the UGOT and DNAlink Incorporation. Diagnostic performance for predicting amyloid PET positivity, cross-laboratory agreement, and the impact of normalization techniques were assessed. Bland-Altman plots and correlation analyses were employed to evaluate agreement and variability. Results: Plasma ptau217 concentrations exhibited strong correlations with amyloid PET global centiloid values, with comparable diagnostic performance between laboratories (area under the curve=0.94 for UGOT and 0.95 for DNAlink). Cross-laboratory agreement for ptau217 was excellent (r=0.96), improving further after natural log transformation. GFAP and NfL also demonstrated moderate to strong correlations (r=0.86 for GFAP and r=0.99 for NfL), with normalization reducing variability. Conclusions Plasma biomarker measurements were consistent across laboratories using identical Simoa platforms, with strong diagnostic performance and improved agreement after normalization. These findings support the scalability of plasma biomarkers for multicenter studies and underscore their potential for standardized applications in AD research and clinical practice.